

## AUROBINDO PHARMA LIMITED

### Details of Familiarisation sessions

Date of programme	Area Covered
09.02.2016	Risk Management - Assessment of Risk
29.03.2016	Familiarisation with the Operations - Presentation & Interaction with Senior Management
23.08.2016	Implications of Goods and Service Tax
14.11.2016	Business operations of subsidiaries in USA
09.02.2017	Internal Financial Control and Compliance Tool
30.03.2017	Familiarisation with the Operations - Presentation & Interaction with Senior Management
29.05.2017	Bio Similar Business, Integrated Reporting and GST
09.11.2017	General Data Protection Regulation (GDPR) compliances
28.02.2018	Induction Program to New Director - Presentation on business operations and Management of the Company
28.03.2018	Familiarisation with the Operations - Presentation & Interaction with Senior Management
28.05.2018	Update on SEBI circulars and Companies amendment Act, 2017
28.05.2018	Update on GDPR compliance program
07.02.2019	Update on Amended Listing Regulations and PIT Regulations
27.03.2019	A presentation on the new developments in the pharma industry, the recent acquisitions by the Company, challenges of integration of these acquisitions with that of the Company for achieving the synergies of acquisitions will be covered apart from normal update about the operations of the Company
12.11.2019	A presentation on the Taxation Laws (Amendment) Ordinance 2019 was made to the Board members
12.11.2019	An update on amendments in the Companies Act, 2013 with regard to new eligibility criteria for appointment and continuation of Independent Directors was provided
06.02.2020	An update on Union Budget 2020-21 was made to the Board members
26.03.2020	A presentation on the new developments in the Pharma industry and update about the operations of the Company was made to the Independent Directors
10.02.2021	Presentation on amendment in CSR Rules.
10.02.2021	An update on maintenance of digital data base as per SEBI (PIT) Regulations,2015.
24.03.2021	A presentation on familiarization on Company's operations in 2020-21
31.05.2021	An update on amendments in SEBI(LODR) Regulations, 2015
28.03.2022	A presentation on familiarization on Company's operations in 2021-22
17.06.2022	An update on the provisions of appointment of Auditors was made to the directors
08.03.2023	An induction programme on business operations of the Company was made to Mr.Santanu Mukherjee
27.03.2023	A presentation on familiarization on Company's operations in 2022-23
01.04.2023	A presentation on operations of Unit 5 and 17
09.11.2023	A Presentation on PLI Scheme
27.03.2024	A presentation that covered on the key developments in the last one year and plans that would drive future growth of the Company in next five years
09.11.2024	An update on framework for considering unaffected share price for transactions upon confirmation of market rumour and industry standards.
09.02.2025	A presentation on Biosimilar Business and update on amendments in SEBI (LODR) Regulations, 2015.
27.03.2025	A presentation on Company overview, Business Highlights, Financial Summary, Key Levers for sustained growth and Environment, Health & Safety Goals
26.05.2025	A presentation on Biosimilar and CMO business.
16.10.2025	Presentations and discussions with business heads of API Business, European Operations, Oncology & Injectables and US Operations.
10.02.2026	Orientation programme on appointment as Independent Director
31.03.2026	A presentation on Company overview, Business Highlights, Financial Summary, Key Levers for sustained growth and Environment, Health & Safety

Details of attendance of Independent Directors in Familiarization Sessions are as follows:

Sl. No.	Name of Independent Director	No of sessions attended		No.of hours spent in the sessions attended	
		FY 2025-26	Cumulative till date	FY 2025-26	Cumulative till date
1	Mr.M.R.Kumar	3	6	4.50	7.00
2	Mr. Girish Paman Vanvari	3	15	4.50	13.25
3	Mr.Santanu Mukherjee	3	11	4.50	11.50
4	Dr.(Mrs.) Deepali Panti Joshi	2	7	3.50	7.00
5	Dr.(Mrs.) Punita Kumar Sinha	2	2	3.00	3.00

Most of the Familiarisation programmes were conducted as part of Board / Committee Meetings.